Latest News

New trials show oral collagen boosts hydration, elasticity and barrier strength in weeks—while wrinkle and dermal density claims remain unproven.

The latest DermView custom video series explored how molecular tools are reshaping management decisions in cutaneous squamous cell carcinoma.

Real-world data show ruxolitinib cream improves facial vitiligo in 3 months, boosting quality of life and imaging-confirmed repigmentation.

New trials show oral psoriasis drugs rival biologics, expand care across ages, and spotlight systemic risks—plus the ongoing fight for access. Read our exclusive recap for PsO Action Month.

The investigational anti–IL-13 monoclonal antibody could change how dermatologists think about biologic dosing in moderate to severe AD.

Imsidolimab gained EU orphan designation for GPP as the IL-36 receptor inhibitor advances toward a December 2026 FDA decision.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Are exosome-derived products legitimate or are they just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Split-face trial finds 34-gauge low-dead-space injector makes upper-face Botox injections hurt less, bruise less, and waste fewer units.

Learn how private equity rollups reshape dermatology—EBITDA deals, MSOs, and the real tradeoffs for owners, PAs, and new grads.

Shanna Miranti, MPAS, PA-C, explores how fertility treatments can affect skin and hair, including acne, melasma, and hair loss, and offers guidance for patient care.

Meta-analysis suggests vitiligo links to lower skin cancer rates, with significantly reduced squamous cell carcinoma; phototherapy shows higher estimates but remains inconclusive.

Phase 3 data from Merck and Moderna show mRNA vaccine intismeran plus pembrolizumab cuts melanoma relapse and spread after surgery, hinting at new adjuvant standard.